PSMA – Medxy AI

Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial

By MedXY 12/08/2025

In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs 7.4 months; HR 0.37) without increased grade ≥3 toxicity.

news Oncology Urology

[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis

By MedXY 11/05/2025

PSMAfore shows that [177Lu]Lu-PSMA-617 given to taxane‑naive, PSMA-positive mCRPC patients delays worsening of health-related quality of life, pain, and first symptomatic skeletal events versus switching AR pathway inhibitors.

Clinical Updates news Oncology Specialties Urology

First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study

By MedXY 08/02/2025

A phase 1/2 trial demonstrates the safety of [161Tb]Tb-PSMA-I&T, a novel dual beta-Auger radioligand, in heavily pretreated metastatic castration-resistant prostate cancer patients, supporting further clinical investigation.